Global Human Microbiome-based Drugs Market - PowerPoint PPT Presentation


PPT – Global Human Microbiome-based Drugs Market PowerPoint presentation | free to download - id: 8704e3-ODc5M


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Global Human Microbiome-based Drugs Market


Bharat Book Bureau provides the report on “Global Human Microbiome-based Drugs Market”, () The report provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market. – PowerPoint PPT presentation

Number of Views:30


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Human Microbiome-based Drugs Market

Global Human Microbiome-based Drugs Market
  • The global market for human microbiome-based
    drugs and diagnostics should reach a market size
    of nearly 9.9 billion by 2024.
  • Study Goals and Objectives
  • The objective of this study is to review the
    development of human microbiome-based drugs and
    diagnostics and assess their market potential for
    the U.S., Europe, Japan, China and rest of world
    geographies. We are particularly interested in
    characterizing the market for microbiome-based
    drugs for various diseases that are linked with
    the dysregulation in human microbiome.
  • A focus of this report is to describe the
    microbial associations of various diseases,
    present a comprehensive profile of the
    microbiome-based drugs in the clinical
    development and finally provide the projections
    on the market size of microbiome-based drugs in
    various disease areas for the time period of 2018
    to 2024.

(No Transcript)
Reasons for Doing This Study
  • The human body is a home to over 100 trillion
    microbes and over 2 million microbial genes.
    Microbiome is a term that represents all of the
    microbial genes. So, the human microbiome is, in
    a sense, our second genome. Microbes residing
    inside and on the human bodies play a significant
    role in the bodys physiological functionssome
    beneficial and others harmful. Our knowledge and
    understanding of the role that microbes play in
    various diseases has grown exponentially since
    the completion of Human Microbiome Project in
    2012. This field has seen a tremendous explosion
    in research and development activities in
    microbiome-based drugs and diagnostics. The field
    has also attracted substantial public and private
    sector investments. Collectively, these
    developments have created a new sectorhuman
    microbiome-based drugs and diagnostics.

Intended Audience
  • We have compiled a study of microbiome-based
    drugs and diagnostics that will be important in
    key end-user segments. We analyze the
    microbiome-based drug market by indication (e.g.,
    cancer, gastrointestinal diseases, metabolic
    disorders etc.), by type of product (e.g., live
    bacteria, engineered bacteria, bacterial mixtures
    etc.), and by region (i.e., the U.S. and the rest
    of the world, which includes Europe, China, Japan
    and other countries).
  • We examine the microbiomes scientific basis in
    various diseases, profile the microbiome products
    under development, and review intellectual
    property, corporate alliances and investments. We
    provide a holistic review of market potential and
    product sales forecasts by disease segment, by
    product and by region for the time period of 2017
    to 2024.

Scope of Report
  • The scope of the study includes the major
    microbiome-based drugs and diagnostics that are
    likely to be commercialized within the next eight
    years. Each product within each market is
    analyzed to determine its market status, market
    potential during the time period of 2018 to 2024.
    Microbiome intellectual property, investments and
    collaborations are discussed.
  • Influencing factors, industry structure,
    challenges facing the industry and patent status
    are discussed. Research examines companies in the
    industry, corporate alliances and assay
    consumption by indication. We profile 25
    companies participating in this rapidly
    developing and evolving sector.

Information Sources
  • Both primary and secondary information sources
    were used in preparing this study. Research
    interviewed life science companies and research
    institutions to obtain data for this study.
    Included were diagnostics, drug firms and leading
    research institutions. In addition, we compiled
    data from secondary sources, including industry,
    trade and government organizations.

  • Research presents an analysis of each of the key
    market segments that will be commercially
    important during the 20172024 period
    microbiome-based drugs for gastrointestinal
    disorders (ulcerative colitis, Crohns disease,
    Clostridium difficle infection, lactose
    intolerance, celiac disease, hepatic
    encephalopathy and non-alcoholic
    steatohepatitis), cancer, bacterial infections
    (recurrent bacterial vaginosis and urinary tract
    infection, dental caries), orphan diseases (urea
    cycle disorders, phenylketonuria) and metabolic
    diseases (type 2 diabetes, obesity). We also
    conducted an analysis of microbiome-based
    diagnostics in various areas of disease.

Full Reports
Global Human Microbiome-based Drugs Market
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Email O
ur Blog https// Twitter
https// Facebook
https// LinkedIn